Acids pharmacokinetics

Cattaneo D, Merlini S, Zenoni S, Baldelli S, Gotti E, Remuzzi G Perico N. (2005) Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. Am J... 

Cloyd, J.C., Fischer, J.H., Kriel, R.L., and Kraus, D.M. (1993) Valproic acid pharmacokinetics in children. IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. Clin Pharmacol Ther 53 22-29. 

Jacobs RF, Trang JM, Kearns GL, et al. Ticarcillin/clavulanic acid pharmacokinetics in children and young adults with cystic fibrosis. J Pediatr 1985 106 1001-1007. 

A prodrug, rapidly metabohzed to 6-methoxy-2-naphthyl-acetic acid pharmacokinetics reflect active compound Evidence for cardiovascular adverse events... 

Vakily, M., Pasutto, F.M. Daneshtalab, M. Jamali, F. Inclusion complexation of heptakis(2,6-di-0-ethyl)-beta-cyclodextrin with tiaprofenic acid pharmacokinetic consequences of a pH-dependent release and stereoselective dissolution. J. Pharm. Sci. 1995, 84, 1014-1019. 

In a study intravenous zoledronic acid 4 mg every 4 weeks with alternate day prednisolone was given with or without thalidomide 200 mg daily for up to 1 year. The zoledronic acid pharmacokinetics were not affected by thalidomide and based on renal function no clinically adverse interaction occurred during concurrent use. The subjects in this study were patients with multiple myeloma with no disease progression 6 weeks after autologous stem-cell transplantation and conditioning with melphalan. ... 

Zucker K, Rosen A, Tsaroucha A, et al. Unexpected augmentation of mycophenoUc acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997 5 225-232. 

Penicillins. Since the discovery of penicillin in 1928 as an antibacterial elaborated by a mold, Penicillium notatum the global search for better antibiotic-producing organism species, radiation-induced mutation, and culture-media modifications have been used to maximize production of the compound. These efforts have resulted in the discovery of a variety of natural penicillins differing in side chains from the basic molecule, 6-aminopenici11anic acid [551-16-6], These chemical variations have produced an assortment of dmgs having diverse pharmacokinetic and antibacterial characteristics (see Antibiotics, P-lactams). 

The separation of enantiomers is a very important topic to the pharmaceutical industry. It is well recognized that the biological activities and bioavailabilities of enantiomers often differ [1]. To further complicate matters, the pharmacokinetic profile of the racemate is often not just the sum of the profiles of the individual enantiomers. In many cases, one enantiomer has the desired pharmacological activity, whereas the other enantiomer may be responsible for undesirable side-effects. What often gets lost however is the fact that, in some cases, one enantiomer may be inert and, in many cases, both enantiomers may have therapeutic value, though not for the same disease state. It is also possible for one enantiomer to mediate the harmful effects of the other enantiomer. For instance, in the case of indacrinone, one enantiomer is a diuretic but causes uric acid retention, whereas the other enantiomer causes uric acid elimination. Thus, administration of a mixture of enantiomers, although not necessarily racemic, may have therapeutic value. 

Poor Metabolizer Phenotype Population Pharmacokinetics Positron Emission Tomography Post-translational Modification Potassium Channels Potassium Competitive Acid Blockers PP... 

McMahon B.M., Mays D., Lipsky J., Stewart J.A., Fauq A., Richelson E. Pharmacokinetics and tissue distribution of a peptide nucleic acid after intravenous administration. Antisense Nucleic Acid Drug Dev. 2002 12 65-70... 

Kristensen E. In vitro and in vivo studies on pharmacokinetics and metabolism of PNA constructs in rodents. In Peptide Nucleic Acids Methods and Protocols, Nielsen P. E. (Ed.). 2002, Humana Press (To-towa, N.J., United States) Copenhagen, pp. 259-269. 

Allen BC, Fisher JW. 1993. Pharmacokinetic modeling of trichloroethylene and trichloroacetic acid in humans. Risk Anal 13 71-86. 

Fisher JW, Whittaker TA, Taylor DH, et al. 1989. Physiologically based pharmacokinetic modeling of the pregnant rat A multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid. Toxicol Appl Pharmacol 99 395-414. 

---